Please use this identifier to cite or link to this item:
http://ir.mu.ac.ke:8080/jspui/handle/123456789/8061
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nuss, Emily E. | - |
dc.contributor.author | Hoffman, Matthew K. | - |
dc.contributor.author | Goudar, Shivaprasad S. | - |
dc.contributor.author | Kavi, Avinash | - |
dc.contributor.author | Metgud, Mrityunjay | - |
dc.contributor.author | Somannavar, Manjunath | - |
dc.contributor.author | Okitawutshu, Jean | - |
dc.contributor.author | Lokangaka, Adrien | - |
dc.contributor.author | Bauserman, Melissa | - |
dc.contributor.author | Mwapule, Abigail | - |
dc.contributor.author | Chomba, Elwyn | - |
dc.contributor.author | Carlo, Waldemar Alberto | - |
dc.date.accessioned | 2023-09-18T13:11:55Z | - |
dc.date.available | 2023-09-18T13:11:55Z | - |
dc.date.issued | 2023 | - |
dc.identifier.uri | https://doi.org/10.1016/j.ajogmf.2023.101095 | - |
dc.identifier.uri | http://ir.mu.ac.ke:8080/jspui/handle/123456789/8061 | - |
dc.description.abstract | Background: The ASPIRIN Trial was a landmark study that demonstrated a reduction in preterm birth (PTB) and hypertensive disorders of pregnancy (HDP) in nulliparous women who received low-dose aspirin (LDA). All women in the study had at least one moderate-risk factor for preeclampsia, nulliparity. Unlike current United States Preventative Service Task Force (USPSTF) guidelines, which recommend LDA for two or more moderate-risk factors, women in this study were randomized to receive LDA regardless of the presence or absence of an additional risk factor. Objective: To compare how low-dose aspirin (LDA) differentially benefits nulliparous women with and without additional preeclampsia risk factors for the prevention of preterm birth (PTB) and hypertensive disorders of pregnancy (HDP). Study design: This is a non-pre-specified secondary analysis of the ASPIRIN trial that randomized nulliparous women with singleton pregnancies from six low-middle income countries to receive LDA or placebo. Our primary exposure was having an additional preeclampsia risk-factor beyond nulliparity. Our primary outcome was PTB before 37 weeks and our secondary outcomes included PTB before 34 weeks, PTB before 28 weeks, HDP, and perinatal mortality. Results: Among 11,558 nulliparous women who met the inclusion criteria, 66.8% had no additional risk factors. LDA similarly reduced the risk of PTB <37 weeks in women with and without additional risk factors (RR 0.75 vs. 0.85, p=0.35). Additionally for our secondary outcomes, LDA similarly reduced the risk of PTB <28 weeks, HDP, and perinatal mortality in women with and without additional risk factors. The reduction of PTB <34 weeks with LDA was significantly greater in women without additional risk factors compared to those with an additional risk factor (RR 0.69 vs. 1.04, p=0.04). Conclusion: LDA's ability to prevent PTB, HDP, and perinatal mortality is similar in nulliparous women with and without additional risk factors. Professional societies should consider recommending LDA to all nulliparous women. | en_US |
dc.language.iso | en | en_US |
dc.subject | Pretem birth prevention | en_US |
dc.title | The impact of risk factors on aspirin's efficacy for the prevention of preterm birth | en_US |
dc.type | Article | en_US |
Appears in Collections: | School of Medicine |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.